Intestinal transplantation (ITx) remains a lifesaving option for patients suffering from
irreversible intestinal failure and complications from total parenteral nutrition. Since its …

Despite improvement in early outcome, rejection particularly chronic allograft enteropathy
continues to be a major barrier to long-term visceral engraftment. The potential role of donor …

Acute cellular rejection remains a serious and frequent complication during the
posttransplant course of small bowel allograft recipients. Currently, small bowel biopsies are …

Intestinal transplantation (ITx) is the only definitive therapy for irreversible intestinal failure.
Owing to the limited short‐and long‐term graft survival over the years, ITx has been a …

Small bowel transplantation can be a life-preserving procedure for patients with irreversible
intestinal failure. Allograft rejection remains a major source of morbidity and mortality and its …

Abstract Heme Oxygen-1 (HO-1)-modified bone marrow mesenchymal stem cells (BMMSCs)
are effective to protect and repair transplanted small bowel and intestinal epithelial cells …

Two-thirds of small-bowel transplantation (SBT) recipients develop bacteremia, with the
majority of infections occurring within 3 months post-transplant. Sepsis-related mortality …

There is a paucity of data on long-term outcomes following visceral transplantation in the
contemporary era. This is a single-center retrospective analysis of all visceral allograft …

To facilitate endoscopic access for rejection surveillance and stenting of the pancreas, we
have abandoned the duodenojejunostomy (DJ) in favor of duodenoduodenostomy (DD) in …

Intestinal transplantation (ITx) remains challenged by frequent/severe rejections and
immunosuppression-related complications (infections/malignancies/drug toxicity). We …